E
BioCorRx Inc.
BICX
$0.3859
$0.059918.37%
E
Sell
3/14/2023Downgrade
BioCorRx Inc. (BICX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
BioCorRx Inc. (BICX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
BioCorRx Inc. (BICX) was upgraded to D from E+ on 02/09/2023.
BioCorRx Inc. (BICX) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
BioCorRx Inc. (BICX) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from -0.18 to -0.16.
BioCorRx Inc. (BICX) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from -0.18 to -0.16.
D
Sell
10/27/2022Upgraded
BioCorRx Inc. (BICX) was upgraded to D from D- on 10/27/2022 due to an increase in the total return index.
BioCorRx Inc. (BICX) was upgraded to D from D- on 10/27/2022 due to an increase in the total return index.
D
Sell
8/17/2022Downgrade
BioCorRx Inc. (BICX) was downgraded to D- from D on 8/17/2022 due to a major decline in the total return index, solvency index and growth index. Earnings per share declined from -$0.1362 to -$0.1873, the quick ratio declined from 0.06 to 0.04, and total revenue declined 21.95% from $20.5 to $16.
BioCorRx Inc. (BICX) was downgraded to D- from D on 8/17/2022 due to a major decline in the total return index, solvency index and growth index. Earnings per share declined from -$0.1362 to -$0.1873, the quick ratio declined from 0.06 to 0.04, and total revenue declined 21.95% from $20.5 to $16.
D
Sell
5/4/2022Upgraded
BioCorRx Inc. (BICX) was upgraded to D from E+ on 05/04/2022.
BioCorRx Inc. (BICX) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
BioCorRx Inc. (BICX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
BioCorRx Inc. (BICX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
BioCorRx Inc. (BICX) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
BioCorRx Inc. (BICX) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
BioCorRx Inc. (BICX) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.21 to 0.03, and debt to equity increased from -0.23 to -0.19.
BioCorRx Inc. (BICX) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.21 to 0.03, and debt to equity increased from -0.23 to -0.19.
D
Sell
11/17/2021Upgraded
BioCorRx Inc. (BICX) was upgraded to D from D- on 11/17/2021 due to an increase in the volatility index and valuation index.
BioCorRx Inc. (BICX) was upgraded to D from D- on 11/17/2021 due to an increase in the volatility index and valuation index.
D
Sell
11/8/2021Downgrade
BioCorRx Inc. (BICX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
BioCorRx Inc. (BICX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
4/5/2021Upgraded
BioCorRx Inc. (BICX) was upgraded to D from D- on 4/5/2021 due to an increase in the growth index and total return index. Operating cash flow increased 42.72% from -$595.8 to -$341.3, and EBIT increased 13.92% from -$2.05M to -$1.77M.
BioCorRx Inc. (BICX) was upgraded to D from D- on 4/5/2021 due to an increase in the growth index and total return index. Operating cash flow increased 42.72% from -$595.8 to -$341.3, and EBIT increased 13.92% from -$2.05M to -$1.77M.
D
Sell
11/18/2020Downgrade
BioCorRx Inc. (BICX) was downgraded to D- from D on 11/18/2020 due to a decline in the solvency index, growth index and total return index. Total revenue declined 11.57% from $33.7 to $29.8, operating cash flow declined 10.37% from -$539.8 to -$595.8, and the quick ratio declined from 0.41 to 0.37.
BioCorRx Inc. (BICX) was downgraded to D- from D on 11/18/2020 due to a decline in the solvency index, growth index and total return index. Total revenue declined 11.57% from $33.7 to $29.8, operating cash flow declined 10.37% from -$539.8 to -$595.8, and the quick ratio declined from 0.41 to 0.37.
D
Sell
7/8/2020Upgraded
BioCorRx Inc. (BICX) was upgraded to D from D- on 7/8/2020 due to an increase in the total return index and volatility index.
BioCorRx Inc. (BICX) was upgraded to D from D- on 7/8/2020 due to an increase in the total return index and volatility index.
D
Sell
6/23/2020Downgrade
BioCorRx Inc. (BICX) was downgraded to D- from D on 6/23/2020 due to a decline in the volatility index.
BioCorRx Inc. (BICX) was downgraded to D- from D on 6/23/2020 due to a decline in the volatility index.
D
Sell
6/8/2020Upgraded
BioCorRx Inc. (BICX) was upgraded to D from D- on 6/8/2020 due to an increase in the growth index, solvency index and volatility index. Operating cash flow increased 24.09% from -$889.2 to -$675, earnings per share increased from -$0.225 to -$0.1999, and EBIT increased 4.87% from -$1.6M to -$1.52M.
BioCorRx Inc. (BICX) was upgraded to D from D- on 6/8/2020 due to an increase in the growth index, solvency index and volatility index. Operating cash flow increased 24.09% from -$889.2 to -$675, earnings per share increased from -$0.225 to -$0.1999, and EBIT increased 4.87% from -$1.6M to -$1.52M.
D
Sell
5/1/2020Downgrade
BioCorRx Inc. (BICX) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
BioCorRx Inc. (BICX) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
D
Sell
3/31/2020Upgraded
BioCorRx Inc. (BICX) was upgraded to D from E+ on 3/31/2020 due to a significant increase in the efficiency index, growth index and solvency index. Debt to equity declined from 5.12 to -0.39, total revenue increased 33.91% from $46.6 to $62.4, and earnings per share increased from -$0.3343 to -$0.225.
BioCorRx Inc. (BICX) was upgraded to D from E+ on 3/31/2020 due to a significant increase in the efficiency index, growth index and solvency index. Debt to equity declined from 5.12 to -0.39, total revenue increased 33.91% from $46.6 to $62.4, and earnings per share increased from -$0.3343 to -$0.225.
E
Sell
10/23/2019Downgrade
BioCorRx Inc. (BICX) was downgraded to E+ from D- on 10/23/2019 due to a noticeable decline in the total return index and volatility index.
BioCorRx Inc. (BICX) was downgraded to E+ from D- on 10/23/2019 due to a noticeable decline in the total return index and volatility index.
D
Sell
8/19/2019Downgrade
BioCorRx Inc. (BICX) was downgraded to D- from D+ on 8/19/2019 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 178.98% from -$323.1 to -$901.4, net income declined 15.19% from -$1.77M to -$2.04M, and EBIT declined 8.07% from -$1.48M to -$1.6M.
BioCorRx Inc. (BICX) was downgraded to D- from D+ on 8/19/2019 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 178.98% from -$323.1 to -$901.4, net income declined 15.19% from -$1.77M to -$2.04M, and EBIT declined 8.07% from -$1.48M to -$1.6M.
D
Sell
3/29/2019Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 3/29/2019 due to a decline in the total return index and volatility index.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 3/29/2019 due to a decline in the total return index and volatility index.
C
Hold
3/13/2019Upgraded
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 3/13/2019 due to an increase in the volatility index and valuation index.
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 3/13/2019 due to an increase in the volatility index and valuation index.
D
Sell
2/26/2019Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 2/26/2019 due to a decline in the volatility index and total return index.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 2/26/2019 due to a decline in the volatility index and total return index.
C
Hold
2/11/2019Upgraded
BioCorRx Inc. (BICXD) was upgraded to C- from D+ on 2/11/2019 due to an increase in the valuation index and volatility index.
BioCorRx Inc. (BICXD) was upgraded to C- from D+ on 2/11/2019 due to an increase in the valuation index and volatility index.
D
Sell
1/22/2019Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 1/22/2019 due to a decline in the valuation index and volatility index.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 1/22/2019 due to a decline in the valuation index and volatility index.
C
Hold
12/31/2018Upgraded
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 12/31/2018 due to an increase in the volatility index.
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 12/31/2018 due to an increase in the volatility index.
D
Sell
12/14/2018Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 12/14/2018 due to a decline in the volatility index and total return index.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 12/14/2018 due to a decline in the volatility index and total return index.
C
Hold
11/19/2018Upgraded
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 11/19/2018 due to an increase in the efficiency index, growth index and volatility index. Operating cash flow increased 20.87% from -$545.2 to -$431.4.
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 11/19/2018 due to an increase in the efficiency index, growth index and volatility index. Operating cash flow increased 20.87% from -$545.2 to -$431.4.
D
Sell
4/6/2018Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 4/6/2018 due to a large decline in the growth index, volatility index and valuation index. EBIT declined 54.96% from -$663.6 to -$1.03M, and earnings per share declined from -$0.0045 to -$0.0065.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 4/6/2018 due to a large decline in the growth index, volatility index and valuation index. EBIT declined 54.96% from -$663.6 to -$1.03M, and earnings per share declined from -$0.0045 to -$0.0065.
C
Hold
8/11/2017Upgraded
BioCorRx Inc. (BICX) was upgraded to C- from D on 8/11/2017 due to a significant increase in the efficiency index, solvency index and growth index. Net income increased 129.49% from -$38.34M to $11.3M, earnings per share increased from -$0.1892 to $0.02, and total revenue increased 56.86% from $134.2 to $210.5.
BioCorRx Inc. (BICX) was upgraded to C- from D on 8/11/2017 due to a significant increase in the efficiency index, solvency index and growth index. Net income increased 129.49% from -$38.34M to $11.3M, earnings per share increased from -$0.1892 to $0.02, and total revenue increased 56.86% from $134.2 to $210.5.
D
Sell
6/8/2017Downgrade
BioCorRx Inc. (BICX) was downgraded to D from D+ on 6/8/2017 due to a noticeable decline in the total return index and efficiency index. Net income declined 2,164.62% from -$1.69M to -$38.34M.
BioCorRx Inc. (BICX) was downgraded to D from D+ on 6/8/2017 due to a noticeable decline in the total return index and efficiency index. Net income declined 2,164.62% from -$1.69M to -$38.34M.
D
Sell
4/24/2017Upgraded
BioCorRx Inc. (BICX) was upgraded to D+ from D on 4/24/2017 due to a significant increase in the total return index and growth index. Earnings per share increased from -$0.0155 to -$0.0093, and operating cash flow increased 39.37% from -$607.8 to -$368.5.
BioCorRx Inc. (BICX) was upgraded to D+ from D on 4/24/2017 due to a significant increase in the total return index and growth index. Earnings per share increased from -$0.0155 to -$0.0093, and operating cash flow increased 39.37% from -$607.8 to -$368.5.
D
Sell
8/18/2016Downgrade
BioCorRx Inc. (BICX) was downgraded to D from D+ on 8/18/2016 due to a significant decline in the efficiency index, growth index and valuation index. Earnings per share declined from -$0.0032 to -$0.01, operating cash flow declined 166.1% from -$276.1 to -$734.7, and EBIT declined 104.21% from -$201.9 to -$412.3.
BioCorRx Inc. (BICX) was downgraded to D from D+ on 8/18/2016 due to a significant decline in the efficiency index, growth index and valuation index. Earnings per share declined from -$0.0032 to -$0.01, operating cash flow declined 166.1% from -$276.1 to -$734.7, and EBIT declined 104.21% from -$201.9 to -$412.3.
D
Sell
7/22/2016Upgraded
BioCorRx Inc. (BICX) was upgraded to D+ from D on 7/22/2016 due to an increase in the volatility index.
BioCorRx Inc. (BICX) was upgraded to D+ from D on 7/22/2016 due to an increase in the volatility index.
D
Sell
7/7/2016Downgrade
BioCorRx Inc. (BICX) was downgraded to D from D+ on 7/7/2016 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 149.98% from $552.4 to -$276.1.
BioCorRx Inc. (BICX) was downgraded to D from D+ on 7/7/2016 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 149.98% from $552.4 to -$276.1.
D
Sell
4/15/2016Upgraded
BioCorRx Inc. (BICX) was upgraded to D+ from D on 4/15/2016 due to a significant increase in the efficiency index. Net income increased 100.77% from -$697.5 to $5.4.
BioCorRx Inc. (BICX) was upgraded to D+ from D on 4/15/2016 due to a significant increase in the efficiency index. Net income increased 100.77% from -$697.5 to $5.4.
D
Sell
3/11/2016Downgrade
BioCorRx Inc. (BICX) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
BioCorRx Inc. (BICX) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
D
Sell
1/12/2016Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 1/12/2016 due to a decline in the total return index and volatility index.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 1/12/2016 due to a decline in the total return index and volatility index.
C
Hold
12/28/2015Upgraded
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 12/28/2015 due to an increase in the total return index and volatility index.
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 12/28/2015 due to an increase in the total return index and volatility index.
D
Sell
11/18/2015Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 11/18/2015 due to a decline in the total return index and solvency index. The quick ratio declined from 0.07 to 0.01.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 11/18/2015 due to a decline in the total return index and solvency index. The quick ratio declined from 0.07 to 0.01.
C
Hold
11/9/2015Upgraded
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 11/9/2015 due to a substantial increase in the volatility index.
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 11/9/2015 due to a substantial increase in the volatility index.
D
Sell
9/14/2015Downgrade
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 9/14/2015 due to a substantial decline in the volatility index.
BioCorRx Inc. (BICX) was downgraded to D+ from C- on 9/14/2015 due to a substantial decline in the volatility index.
C
Hold
8/13/2015Upgraded
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 8/13/2015 due to an increase in the valuation index, efficiency index and solvency index. Net income increased 1,755.66% from -$203.2 to -$3.77M, debt to equity declined from 6.4 to -0.55, and the quick ratio increased from 0.04 to 0.07.
BioCorRx Inc. (BICX) was upgraded to C- from D+ on 8/13/2015 due to an increase in the valuation index, efficiency index and solvency index. Net income increased 1,755.66% from -$203.2 to -$3.77M, debt to equity declined from 6.4 to -0.55, and the quick ratio increased from 0.04 to 0.07.
D
Sell
4/2/2015Upgraded
BioCorRx Inc. (BICX) was upgraded to D+ from D on 4/2/2015 due to an increase in the efficiency index, growth index and valuation index. EBIT increased 997.51% from -$184.8 to -$2.03M, net income increased 422.87% from -$383.9 to -$2.01M, and earnings per share increased from -$0.0027 to -$0.0138.
BioCorRx Inc. (BICX) was upgraded to D+ from D on 4/2/2015 due to an increase in the efficiency index, growth index and valuation index. EBIT increased 997.51% from -$184.8 to -$2.03M, net income increased 422.87% from -$383.9 to -$2.01M, and earnings per share increased from -$0.0027 to -$0.0138.
D
Sell
4/15/2014Downgrade
Fresh Start Private Management Inc. (BICX) was downgraded to D from C on 4/15/2014 due to a significant decline in the efficiency index, growth index and solvency index. Debt to equity increased from 0.44 to 4.08, operating cash flow declined 740.45% from -$39.8 to $254.9, and total revenue declined 262.08% from $277.4 to -$449.6.
Fresh Start Private Management Inc. (BICX) was downgraded to D from C on 4/15/2014 due to a significant decline in the efficiency index, growth index and solvency index. Debt to equity increased from 0.44 to 4.08, operating cash flow declined 740.45% from -$39.8 to $254.9, and total revenue declined 262.08% from $277.4 to -$449.6.
OTC PK
03/07/2025 3:12PM Eastern
Quotes delayed
